Showing results (101-110 of 129) with videos related to
Sort By:
Pageof 13
American Journal of Cancer Research|February 13, 2023
Clinical features of patients with MTAP-deleted bladder cancerAndre L De Souza, Anthony E Mega, John Douglass, et al.Blood Advances|September 22, 2021
Detection of clonotypic DNA in the cerebrospinal fluid as a marker of central nervous system invasion in lymphomaAdam J Olszewski, Anna D Chorzalska, Max Petersen, et al.British Journal of Haematology|November 10, 2022
Transcriptomics of acute myeloid leukaemia core bone marrow biopsies reveals distinct therapy response-specific osteo-mesenchymal profilesDiana O Treaba, Dennis M Bonal, Anna Chorzalska, et al.Blood|July 29, 2025
HiJAKing the Hematopoietic System: A Low-Frequency JAK2V617F Clone Drives Myeloproliferative Neoplasm PathologyDennis M Bonal, Alissa Oakes, Anna Chorzalska, et al.Blood Advances|June 14, 2023
Impact of detectable monoclonal protein at diagnosis on outcomes in marginal zone lymphoma: a multicenter cohort studyNarendranath Epperla, Qiuhong Zhao, Reem Karmali, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 7, 2024
Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk DiseaseMatthew S Davids, Christine E Ryan, Benjamin L Lampson, et al.Nature Medicine|December 10, 2023
Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trialLihua E Budde, Adam J Olszewski, Sarit Assouline, et al.Journal of Hematology & Oncology|May 9, 2023
Impact of early relapse within 24 months after first-line systemic therapy (POD24) on outcomes in patients with marginal zone lymphoma: A US multisite studyNarendranath Epperla, Rina Li Welkie, Pallawi Torka, et al.Blood|September 15, 2018
Bone marrow-specific loss ofAnna Chorzalska, John Morgan, Nagib Ahsan, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2025
Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO TrialLihua E Budde, Huilai Zhang, Won-Seog Kim, et al.Pageof 13